Aurinia Pharmaceuticals (AUPH) Net Margin (2019 - 2026)
Aurinia Pharmaceuticals' (AUPH) quarterly Net Margin came in at 44.21% in Q1 2026, up 684.0% YoY from 5.64% in Q1 2025, and down 83.83% on a QoQ basis from 273.35% in Q4 2025.
Aurinia Pharmaceuticals (AUPH) Net Margin (2019 - 2026) Analysis & Trends
Aurinia Pharmaceuticals (AUPH) has 8 years of Net Margin data on file, last reported at 44.21% in Q1 2026.
- Quarterly Net Margin rose 684.0% year-over-year to 44.21% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 99.99% (up 8388.0% YoY) and the FY2025 annual result came in at 101.47%, up 9902.0% from the prior year.
- Net Margin declined to 44.21% in Q1 2026, from 273.35% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 273.35% in Q4 2025 to a low of 174.01% in Q1 2022.
- A 5-year average of 9.62% and a median of 16.12% in 2022 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2022 — Net Margin soared 533791 bps — and 2023, when it plunged 855 bps.
- Tracing AUPH's Net Margin over 5 years: stood at 91.5% in 2022, then surged by 35 bps to 59.58% in 2023, then surged by 104 bps to 2.47% in 2024, then soared by 10980 bps to 273.35% in 2025, then sank by 84 bps to 44.21% in 2026.
- The last three Net Margin figures came in at 44.21% (Q1 2026), 273.35% (Q4 2025), and 42.96% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Aurinia Pharmaceuticals | 2.06 Bn | 1.61 Bn | 76.67 Mn | 44.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44.92% |
| Mar 31, 2026 | 44.21% |
| Dec 31, 2025 | 273.35% |
| Sep 30, 2025 | 42.96% |
| Jun 30, 2025 | 30.79% |
| Mar 31, 2025 | 37.37% |
| Dec 31, 2024 | 2.47% |
| Sep 30, 2024 | 21.11% |
| Jun 30, 2024 | 1.26% |
| Mar 31, 2024 | -21.29% |
| Dec 31, 2023 | -59.58% |
| Sep 30, 2023 | -24.67% |
| Jun 30, 2023 | -27.70% |
| Mar 31, 2023 | -76.16% |
| Dec 31, 2022 | -91.50% |
| Sep 30, 2022 | -16.12% |
| Jun 30, 2022 | -125.98% |
| Mar 31, 2022 | -174.01% |
| Dec 31, 2021 | -142.38% |
| Sep 30, 2021 | -342.64% |